TY - JOUR
T1 - Nonlymphoblastic lymphoma in children - Histology and stage-related response to therapy
T2 - A pediatric oncology group study
AU - Hvizdala, E. V.
AU - Berard, C.
AU - Callihan, T.
AU - Falletta, J.
AU - Sabio, H.
AU - Shuster, J. J.
AU - Sullivan, M.
AU - Wharam, M. D.
PY - 1991
Y1 - 1991
N2 - From May 1979 to March 1983, 93 eligible patients with nonlymphoblastic lymphoma (NLBL) were treated by members of the Pediatric Oncology Group (POG) with Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), vincristine, prednisone, cyclophosphamide, and mercaptopurine (ACOP+); CNS prophylaxis with intrathecal (IT) methotrexate, hydrocortisone, and cranial irradiation (2,400 rads), and radiation therapy to the primary disease were administered in stages I and II, and to residual disease in stages III and IV. Duration of treatment was 2 years for stages I, II, and III and 3 years for stage IV disease. Of the 93 patients entered onto the study, 47 had diffuse small noncleaved-cell lymphoma (DSNCL), 38 had diffuse large-cell lymphoma (DLCL), and eight had other histologies. Localized disease (stages I and II) was present in 51 patients, and 42 had advanced (stages III and IV) disease. The study confirmed previously reported importance of stage with a 4-year event-free survival (EPS) of 78% (SE ± 7%) for patients with localized disease as compared with 44% (SE ± 9%) in patients with advanced disease (P ≤ .001). In localized disease, seven of 11 adverse events occurred in patients who were off therapy and more than 30 months after the initial diagnosis (relapse, three; second malignancy, two; death in remission, two). Large-cell histology proved to be an important prognostic factor in patients with stages III and IV disease with EFS at 4 years of 67% (SE ± 11%) for DLCL versus 17% (SE ± 11%) for DSNCL (P ≤ .001). We conclude that it is important to distinguish histologically between small noncleaved-cell and large-cell types of NLBL as a basis for further controlled clinical trials.
AB - From May 1979 to March 1983, 93 eligible patients with nonlymphoblastic lymphoma (NLBL) were treated by members of the Pediatric Oncology Group (POG) with Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), vincristine, prednisone, cyclophosphamide, and mercaptopurine (ACOP+); CNS prophylaxis with intrathecal (IT) methotrexate, hydrocortisone, and cranial irradiation (2,400 rads), and radiation therapy to the primary disease were administered in stages I and II, and to residual disease in stages III and IV. Duration of treatment was 2 years for stages I, II, and III and 3 years for stage IV disease. Of the 93 patients entered onto the study, 47 had diffuse small noncleaved-cell lymphoma (DSNCL), 38 had diffuse large-cell lymphoma (DLCL), and eight had other histologies. Localized disease (stages I and II) was present in 51 patients, and 42 had advanced (stages III and IV) disease. The study confirmed previously reported importance of stage with a 4-year event-free survival (EPS) of 78% (SE ± 7%) for patients with localized disease as compared with 44% (SE ± 9%) in patients with advanced disease (P ≤ .001). In localized disease, seven of 11 adverse events occurred in patients who were off therapy and more than 30 months after the initial diagnosis (relapse, three; second malignancy, two; death in remission, two). Large-cell histology proved to be an important prognostic factor in patients with stages III and IV disease with EFS at 4 years of 67% (SE ± 11%) for DLCL versus 17% (SE ± 11%) for DSNCL (P ≤ .001). We conclude that it is important to distinguish histologically between small noncleaved-cell and large-cell types of NLBL as a basis for further controlled clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=0025735395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025735395&partnerID=8YFLogxK
U2 - 10.1200/JCO.1991.9.7.1189
DO - 10.1200/JCO.1991.9.7.1189
M3 - Article
C2 - 2045859
AN - SCOPUS:0025735395
SN - 0732-183X
VL - 9
SP - 1189
EP - 1195
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 7
ER -